Simulect

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved May 1998

Specific Treatments:

acute organ transplant rejection

Find Related Trials for The Following Conditions

General Information

Simulect has been approved for acute rejection episodes in renal transplant recipients.

Mechanism of Action

Simulect works by blocking the receptor for IL-2, a protein that simulates proliferation of T-lymphocytes, which play a key role in organ transplant rejection.